How to use a noninferiority trial: Users' guides to the medical literature

JAMA

Volumn 308, Issue 24, 2012, Pages 2605-2611

  Mulla, Sohail M ^a   Scott, Ian A ^b   Jackevicius, Cynthia A ^c,d,e,f,g   You, John J ^a,c   Guyatt, Gordon H ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RIVAROXABAN; WARFARIN;

CEREBROVASCULAR ACCIDENT; CONSERVATIVE TREATMENT; EMBOLISM; HEART FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; MEDICAL LITERATURE; NONINFERIORITY TRIAL; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VALIDITY; VENOUS THROMBOEMBOLISM;

EID: 84871529395     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/2012.jama.11235     Document Type: Review

References (21)

1. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open- label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-48.
2. Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27(3):317-332.
3. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145(1):62-69.
4. Temple R, O'Neill R. Guidance for Industry Non-Inferiority Clinical Trials. Rockville, MD: Food and Drug Administration, Department of Health and Human Services; 2010.
5. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295(10):1147-1151.
6. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-2604.
7. Scott IA. Non-inferiority trials: determining whether alternative treatments are good enough. Med J Aust. 2009;190(6):326-330.
8. Gøtzsche PC. Lessons from and cautions about non-inferiority and equivalence randomized trials. JAMA. 2006;295(10):1172-1174.
9. Schumi J, Wittes JT. Through the looking glass: understanding noninferiority. Trials. 2011;12:106.
10. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
11. Jackson K, Gersh BJ, Stockbridge N, et al; Duke Clinical Research Institute/American Heart Journal Expert Meeting on Antithrombotic Drug Development for Atrial Fibrillation. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. Am Heart J. 2008;155(5):829-840.
12. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
13. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation - regulatory considerations. N Engl J Med. 2011;365(17):1557-1559.
14. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.
15. Kunz R, Guyatt G. Which patients to include in the analysis? Transfusion. 2006;46(6):881-884.
16. Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165(10):1339-1341.
17. Willenheimer R, van Veldhuisen DJ, Silke B, et al; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426-2435.
18. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in metaanalyses: retrospective cohort study. BMJ. 2007;335(7631):1202-1205.
19. Nout RA, Smit VT, Putter H, et al; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010; 375(9717):816-823.
20. Guyatt GH, Haynes RB, Jaeschke RZ, et al; Evidence-Based Medicine Working Group. Users'Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users'Guides to patient care. JAMA. 2000;284(10):1290-1296.
21. MacLean S, Mulla S, Akl EA, et al; American College of Chest Physicians. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e1S-e23S.